{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T09:06:56Z","timestamp":1777540016289,"version":"3.51.4"},"reference-count":9,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,10,18]],"date-time":"2017-10-18T00:00:00Z","timestamp":1508284800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:sec><jats:title>Adverse Event<\/jats:title><jats:p>A drug interaction leading to higher exposure to cyclosporine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Drugs Implicated<\/jats:title><jats:p>Cyclosporine and ticagrelor.<\/jats:p><\/jats:sec><jats:sec><jats:title>The Patient<\/jats:title><jats:p>A 49\u2010year\u2010old man with a stable renal graft, managed with cyclosporine with stable trough blood concentrations for several years, was treated with ticagrelor for unstable angina pectoris.<\/jats:p><\/jats:sec><jats:sec><jats:title>Evidence That Links the Drug to the Event<\/jats:title><jats:p>The timeline was consistent with the appearance of an interaction, the interaction was confirmed by an increase in trough concentration of cyclosporine, and there were no alternative causes that by themselves could have caused the increase in cyclosporine exposure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Management<\/jats:title><jats:p>Cessation of ticagrelor.<\/jats:p><\/jats:sec><jats:sec><jats:title>Mechanism<\/jats:title><jats:p>Inhibition of CYP3A4 and P\u2010glycoprotein by ticagrelor.<\/jats:p><\/jats:sec><jats:sec><jats:title>Implications for Therapy<\/jats:title><jats:p>Clinicians should be aware of this potential interaction as ticagrelor is frequently prescribed in individuals using cyclosporine. Close monitoring of cyclosporine serum concentrations is warranted to avoid overdosing of cyclosporine. A pharmacokinetic study is needed to further examine the probable interaction between cyclosporine and ticagrelor.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.13433","type":"journal-article","created":{"date-parts":[[2017,9,11]],"date-time":"2017-09-11T09:12:40Z","timestamp":1505121160000},"page":"208-210","source":"Crossref","is-referenced-by-count":5,"title":["Co\u2010administration of cyclosporine and ticagrelor may lead to a higher exposure to cyclosporine: a case report of a 49\u2010year\u2010old man"],"prefix":"10.1111","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2870-482X","authenticated-orcid":false,"given":"Thomas T.","family":"van Sloten","sequence":"first","affiliation":[{"name":"Department of Internal Medicine M\u00e1xima Medical Center  Veldhoven The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A. G.","family":"de Klaver","sequence":"additional","affiliation":[{"name":"Department of Pharmacology M\u00e1xima Medical Center  Veldhoven The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Warmold L.","family":"van den Wall Bake","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine M\u00e1xima Medical Center  Veldhoven The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,10,18]]},"reference":[{"issue":"3","key":"e_1_2_3_2_1","first-page":"S1","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group","year":"2009","journal-title":"Am J Transplant"},{"key":"e_1_2_3_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0290-2"},{"key":"e_1_2_3_4_1","first-page":"1201","article-title":"A compartmental pharmacokinetic model of cyclosporin and its predictive performance after Bayesian estimation in kidney and simultaneous pancreas\u2010kidney transplant recipients","volume":"18","author":"Cremers SC","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"e_1_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1201\/b14003-6"},{"key":"e_1_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-013-1543-3"},{"key":"e_1_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"e_1_2_3_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-014-0205-2"},{"key":"e_1_2_3_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv1037"},{"key":"e_1_2_3_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13354"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13433","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13433","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T04:08:22Z","timestamp":1696046902000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.13433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,18]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1111\/bcp.13433"],"URL":"https:\/\/doi.org\/10.1111\/bcp.13433","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,18]]}}}